Originally published as JCO Early Release 10.1200/JCO.2005.04.192 on July 18 2005
Journal of Clinical Oncology, Vol 23, No 24 (August 20), 2005: pp. 5474-5483
© 2005 American Society of Clinical Oncology.
Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results
Hope S. Rugo,
Roy S. Herbst,
Glenn Liu,
John W. Park,
Merrill S. Kies,
Heidi M. Steinfeldt,
Yazdi K. Pithavala,
Steven D. Reich,
James L. Freddo,
George Wilding
From the University of California, San Francisco Comprehensive Cancer Center, San Francisco; Pfizer Global Research and Development, San Diego, CA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; The University of Texas M.D. Anderson Cancer Center, Houston, TX
Address reprint requests to George Wilding, MD, University of Wisconsin Comprehensive Cancer Center, K4/610 CSC, 600 Highland Ave, Madison, WI 53792; e-mail: gxw{at}medicine.wisc.edu
PURPOSE: We studied the safety, clinical activity, and pharmacokinetics (PK) of AG-013736, an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet-derived growth factor, and c-Kit, in patients with advanced cancer.
PATIENTS AND METHODS: Patients received fixed doses of AG-013736 orally in 28-day cycles. In the first cohort, patients initially received two single test doses of AG-013736 (10 and 30 mg); subsequent dosing was determined by individual PK parameters. Doses in subsequent cohorts were assigned by using a traditional dose-escalation/de-escalation rule based on observed toxicities in the current and previous cohorts. PK analysis included evaluation of the effect of food and antacid.
RESULTS: Thirty-six patients received AG-013736 at doses ranging from 5 to 30 mg by mouth twice daily. The dose-limiting toxicities observed included hypertension, hemoptysis, and stomatitis and were seen primarily at the higher dose levels. The observed hypertension was manageable with medication. Stomatitis was generally tolerable and managed by dose reduction or drug holidays. AG-013736 was absorbed rapidly, with peak plasma concentrations observed within 2 to 6 hours after dosing. The maximum-tolerated dose and recommended phase II dose of AG-013736 is 5 mg, twice daily, administered in the fasted state. No significant drug interaction with antacid was seen. There were three confirmed partial responses and other evidence of clinical activity.
CONCLUSION: In this study, we have demonstrated clinical activity and safety of AG-013736 in patients with advanced solid tumors and identified the dose for phase II testing. The unique phase I study design allowed early identification of important absorption and metabolic issues critical to phase II testing of this agent.
Research support provided by Pfizer Global Research and Development, San Diego, CA, and Groton, CT.
Presented at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics, 2003, Boston, MA; 6th International Symposium on Antiangiogenesis Agents, 2004, San Diego, CA; and American Society of Clinical Oncology Annual Meeting, 2004, New Orleans, LA.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
Related Editorial
- Imaging and Other Biomarkers in Early Clinical Studies: One Step at a Time or Re-Engineering Drug Development?
Jerry M. Collins
JCO 2005 23: 5417-5419
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
C. P. Carden, J. M.G. Larkin, and M. A. Rosenthal
What is the risk of intracranial bleeding during anti-VEGF therapy?
Neuro-oncol,
August 1, 2008;
10(4):
624 - 630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. O. Curwen, H. L. Musgrove, J. Kendrew, G. H.P. Richmond, D. J. Ogilvie, and S. R. Wedge
Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy
Clin. Cancer Res.,
May 15, 2008;
14(10):
3124 - 3131.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Ma and D. J. Waxman
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib
Mol. Cancer Ther.,
January 1, 2008;
7(1):
79 - 89.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Costa and H. A. Drabkin
Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Oncologist,
December 1, 2007;
12(12):
1404 - 1415.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. V. Heymach, B. E. Johnson, D. Prager, E. Csada, J. Roubec, M. Pesek, I. Spasova, C. P. Belani, I. Bodrogi, S. Gadgeel, et al.
Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non Small-Cell Lung Cancer
J. Clin. Oncol.,
September 20, 2007;
25(27):
4270 - 4277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Agulnik, E. W.E. Cohen, R. B. Cohen, E. X. Chen, E. E. Vokes, S. J. Hotte, E. Winquist, S. Laurie, D. N. Hayes, J. E. Dancey, et al.
Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands
J. Clin. Oncol.,
September 1, 2007;
25(25):
3978 - 3984.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. S. Rosen, R. Kurzrock, M. Mulay, A. Van Vugt, M. Purdom, C. Ng, J. Silverman, A. Koutsoukos, Y.-N. Sun, M. B. Bass, et al.
Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors
J. Clin. Oncol.,
June 10, 2007;
25(17):
2369 - 2376.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Thomas, T Trarbach, C Bartel, D Laurent, A Henry, M Poethig, J Wang, E Masson, W Steward, U Vanhoefer, et al.
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer
Ann. Onc.,
April 1, 2007;
18(4):
782 - 788.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. George
Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma
Clin. Cancer Res.,
January 15, 2007;
13(2):
753s - 757s.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Provenzale
Imaging of Angiogenesis: Clinical Techniques and Novel Imaging Methods
Am. J. Roentgenol.,
January 1, 2007;
188(1):
11 - 23.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone
Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions
Oncologist,
July 1, 2006;
11(7):
753 - 764.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Cao, P. C. Sundgren, C. I. Tsien, T. T. Chenevert, and L. Junck
Physiologic and Metabolic Magnetic Resonance Imaging in Gliomas
J. Clin. Oncol.,
March 10, 2006;
24(8):
1228 - 1235.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Collins
Imaging and Other Biomarkers in Early Clinical Studies: One Step at a Time or Re-Engineering Drug Development?
J. Clin. Oncol.,
August 20, 2005;
23(24):
5417 - 5419.
[Full Text]
[PDF]
|
 |
|
|